How Do Buccal Troches Deliver Nutrients and Compounds Directly into the Bloodstream?

Buccal troches, also referred to as lozenges or pastilles, are small dissolvable tablets designed to melt in the mouth rather than be swallowed whole. Typically placed between the cheek and gums, they soften and dissolve at body temperature (approximately 37°C), gradually releasing their active ingredients.

Unlike conventional pills or capsules, which must survive stomach acid, digestive enzymes, and first-pass metabolism in the liver, buccal troches allow certain compounds to enter the bloodstream directly through the oral mucosa. This delivery method has been used for decades by compounding pharmacists and is now experiencing renewed interest as clinicians and formulators seek more efficient, predictable, and patient-friendly ways to deliver targeted compounds.

This article explores how buccal troches work, why the cheek lining is uniquely suited for absorption, and when this delivery method makes scientific sense.

Why Buccal Delivery Is Different from Swallowing a Pill

When a pill is swallowed, its contents take a long and biologically expensive journey. After dissolving in the stomach or intestine, the compound must be absorbed through the gut wall and then processed by the liver before reaching systemic circulation. Along the way, a meaningful portion of the dose may be degraded or inactivated.

Buccal delivery takes a shortcut. As a troche dissolves slowly in the mouth, its active ingredients can be absorbed directly across the cheek lining into the bloodstream. This route bypasses stomach acid, digestive enzymes, and first-pass metabolism in the liver, all of which often limit the effectiveness of oral pills.

The practical result is often a faster onset of action and, for certain compounds, a substantially higher bioavailability compared with swallowing the same dose.

The Buccal Mucosa: Built for Absorption

The buccal mucosa is the inner lining of the cheeks and lips. Unlike the hard palate or gums, which are thick and keratinized, the buccal lining is thin, non-keratinized, and highly vascularized. Capillaries sit just beneath the surface, creating an efficient interface for systemic absorption.

Although “buccal” and “sublingual” are sometimes used interchangeably, they refer to distinct absorption sites. Sublingual administration occurs under the tongue, where the mucosa is only one cell layer thick and absorption is very rapid. Buccal administration occurs through an eight-layer epithelium, which allows for steadier, more controlled uptake. For this reason, troches are commonly designed for cheek placement rather than under the tongue, balancing absorption efficiency with comfort and sustained release.

How Compounds Cross the Buccal Lining (Absorption Mechanisms)

Most compounds absorbed through the buccal mucosa do so via passive diffusion. The majority travel between cells (the intercellular route), while small, lipophilic molecules may also pass directly through cells (the transcellular route).

The rate and extent of absorption depend on multiple factors, including molecular size, polarity, lipid solubility, concentration gradient, and tissue thickness. Because the buccal mucosa lacks the dense keratin barrier found in skin, it presents relatively low resistance to appropriately formulated compounds.

What Makes a Buccal Troche Effective

Troches are not simply pills that dissolve in the mouth. They are deliberately engineered for transmucosal delivery.

Many formulations incorporate mucoadhesive polymers that allow the troche to gently adhere to the cheek lining, increasing contact time and reducing loss into saliva. Troches are also designed to dissolve slowly, maintaining a steady concentration of the active ingredient at the absorption site rather than delivering it all at once.

Some troches are formulated to encourage directional release, favoring movement of the compound into the mucosa rather than into the oral cavity. In certain cases, additional formulation strategies are used to protect sensitive compounds or enhance permeation.

In real-world use, not all of a troche’s dose is absorbed through the cheek; some is inevitably swallowed with saliva. However, even partial transmucosal absorption can meaningfully increase bioavailability because the absorbed fraction bypasses gastrointestinal and hepatic metabolism.

Common Applications of Buccal Troches

Buccal troches are best suited for potent compounds that are effective at relatively low doses.

Hormone troches, such as progesterone, are a well-established example. Buccal delivery allows for sustained absorption while avoiding first-pass liver metabolism, often resulting in more stable systemic levels. Nicotine lozenges are another familiar case, with buccal and sublingual absorption providing rapid relief of cravings.

Certain vitamins (most notably vitamin B12) are also commonly delivered via lozenges or troches. While the clinical superiority of buccal over oral B12 remains debated, many practitioners favor lozenge forms for patients with gastrointestinal absorption challenges or intrinsic factor deficiency.

Advantages of Buccal Troches

One of the primary advantages of buccal troches is improved bioavailability for compounds that are poorly absorbed or extensively metabolized when swallowed. Substances absorbed through the buccal mucosa enter systemic circulation directly, bypassing first-pass liver metabolism.

For some drugs, this difference is dramatic. Nitroglycerin, for example, has less than 1% bioavailability when swallowed but approximately 35-40% when absorbed through oral mucosa. Buccal fentanyl formulations have also demonstrated significantly higher systemic exposure compared with swallowed doses.

Buccal absorption is also fast. Because the cheek lining is richly vascularized, uptake can begin within minutes — much faster than waiting for gastric emptying and intestinal absorption. Troches are non-invasive, discreet, and convenient, particularly for individuals who have difficulty swallowing pills.

Additionally, because troches dissolve slowly, they can provide steadier input over time, smoothing blood levels and reducing peaks and troughs. Many troches are scored, allowing for precise dose titration. Avoiding first-pass metabolism often means that lower doses can achieve the same systemic effect, potentially reducing side effects.

Limitations and Considerations of Buccal Troches

Despite their advantages, buccal troches are not appropriate for every compound.

The total surface area available for absorption in the mouth is limited, restricting the dose that can be delivered. Troches are therefore impractical for large or dilute drugs. Saliva also presents a challenge: continuous salivary flow dilutes dissolved compounds and can carry them away before full absorption occurs.

For this reason, patients are typically advised not to eat, drink, or excessively swallow for 15-30 minutes after placing a troche. Taste and stability in saliva are also important, as unpleasant flavors can reduce adherence.

Absorption can vary between individuals due to differences in saliva flow, mucosal thickness, and oral pH. Improper technique, such as chewing the troche or moving it around, can further reduce effectiveness. Finally, because buccal delivery bypasses first-pass metabolism, compounds normally deactivated by the liver may reach higher systemic levels than expected, underscoring the importance of thoughtful dosing.

Why Troscriptions Uses Buccal Troches

At Troscriptions, buccal troches are not an afterthought. They are a deliberate delivery choice.

Troscriptions troches are physician-formulated, precision-dosed, and designed specifically for transmucosal absorption. The goal is not novelty, but efficiency: delivering well-researched compounds in a way that respects human physiology and maximizes predictable uptake. Each troche is scored for easy titration, allowing individuals to find their lowest effective dose rather than defaulting to a one-size-fits-all approach.

Troscriptions applies pharmaceutical-grade manufacturing standards and rigorous ingredient verification, pairing thoughtful formulation with a delivery system that works with the body rather than against it. The result is a format that offers rapid onset, consistent effects, and practical flexibility — whether the goal is focus, calm, sleep support, or immune resilience.

Buccal troches are not magic. They are simply a smart application of anatomy, pharmacokinetics, and formulation science. When used appropriately, they offer a powerful and time-tested way to deliver targeted compounds efficiently — exactly why Troscriptions continues to invest in doing them the right way.

Conclusion

Buccal troches provide a direct and physiologically sound route for delivering certain compounds into the bloodstream through the cheek lining. By dissolving in the mouth, they take advantage of the highly vascular, permeable buccal mucosa to bypass gastrointestinal degradation and first-pass liver metabolism, often resulting in faster onset and improved bioavailability compared with swallowed pills.

This delivery method is most appropriate for compounds that are poorly absorbed orally, extensively metabolized by the liver, or when a rapid or steady systemic effect is clinically desirable. At the same time, the limited absorption surface and continual saliva flow mean that buccal troches are not suitable for every substance, underscoring the importance of thoughtful formulation and proper use.

For health professionals and consumers alike, an evidence-based understanding of buccal delivery helps ensure troches are used where they make scientific sense. When applied appropriately, buccal troches offer a well-established and effective way to deliver targeted compounds efficiently and predictably.

The following references provide additional scientific context for the concepts discussed above.

References

[1]         H. Zhang, J. Zhang, J.B. Streisand, Oral Mucosal Drug Delivery: Clinical Pharmacokinetics and Therapeutic Applications, Clinical Pharmacokinetics 41 (2002) 661–680. https://doi.org/10.2165/00003088-200241090-00003.

[2]         Mg. Ritu, I. Mohd, S. Sunny, G. Neeraj, A clinical perspective on mucoadhesive buccal drug delivery systems, J Biomed Res 28 (2014) 81. https://doi.org/10.7555/JBR.27.20120136.

[3]         G. Pickering, N. Macian, F. Libert, J.-M. Cardot, S. Coissard, P. Perovitch, M. Maury, C. Dubrey, Buccal acetaminophen provides fast analgesia: two randomized clinical trials in healthy volunteers, DDDT (2014) 1621. https://doi.org/10.2147/DDDT.S63476.

[4]         S. Hua, Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration, Front. Pharmacol. 10 (2019) 1328. https://doi.org/10.3389/fphar.2019.01328.

[5]         T.L. Brown, S. Petrovski, H.T. Chan, M.J. Angove, J. Tucci, Semi-Solid and Solid Dosage Forms for the Delivery of Phage Therapy to Epithelia, Pharmaceuticals (Basel) 11 (2018) 26. https://doi.org/10.3390/ph11010026.

[6]         K. Crowley, S.T. De Vries, G. Moreno-Sanz, Self-Reported Effectiveness and Safety of Trokie® Lozenges: A Standardized Formulation for the Buccal Delivery of Cannabis Extracts, Front. Neurosci. 12 (2018) 564. https://doi.org/10.3389/fnins.2018.00564.

[7]         K. Keane, P. Hinchliffe, N. Namdar, J. Conceicao, P. Newsholme, J. Yovich, Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization, DDDT (2015) 5569. https://doi.org/10.2147/DDDT.S92467.

[8]         N. Salamatmiller, M. Chittchang, T. Johnston, The use of mucoadhesive polymers in buccal drug delivery, Advanced Drug Delivery Reviews 57 (2005) 1666–1691. https://doi.org/10.1016/j.addr.2005.07.003.

[9]         V.V. Khutoryanskiy, Advances in Mucoadhesion and Mucoadhesive Polymers, Macromolecular Bioscience 11 (2011) 748–764. https://doi.org/10.1002/mabi.201000388.

[10]       J.D. Smart, Buccal drug delivery, Expert Opinion on Drug Delivery 2 (2005) 507–517. https://doi.org/10.1517/17425247.2.3.507.

[11]       B.G. Wren, R.O. Day, A.J. McLachlan, K.M. Williams, Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women, Climacteric 6 (2003) 104–111.

[12]       J.E. Rose, F.M. Behm, T.L. Botts, D.R. Botts, P.N. Willette, F. Vocci, J. McCarty, Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy, Psychopharmacology 239 (2022) 2853–2862. https://doi.org/10.1007/s00213-022-06171-z.

[13]      S. Rossi, G. Sandri, C.M. Caramella, Buccal drug delivery: A challenge already won?, Drug Discovery Today: Technologies 2 (2005) 59–65. https://doi.org/10.1016/j.ddtec.2005.05.018. 

[14]       G. Iorgulescu, Saliva between normal and pathological. Important factors in determining systemic and oral health, J Med Life 2 (2009) 303–307.